Pimitespib demonstrated illness stability in 66.7% of sufferers with superior GIST in an expanded entry program, reinforcing its security and efficacy profile.Therapy with...
Early detection, customized therapy and robust help methods are key to bettering outcomes for a number of myeloma sufferers, Dr. Joseph Mikhael explains.Early...
Lenvima plus Keytruda together with TACE improved outcomes for sufferers with unresectable non-metastatic hepatocellular carcinoma.Amongst sufferers with unresectable, non-metastatic hepatocellular carcinoma, therapy with...
